OPKO Health, Inc. $OPK Shares Sold by Y.D. More Investments Ltd

Y.D. More Investments Ltd reduced its position in shares of OPKO Health, Inc. (NASDAQ:OPK) by 13.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,528,899 shares of the biotechnology company’s stock after selling 244,048 shares during the period. Y.D. More Investments Ltd owned 0.19% of OPKO Health worth $2,013,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Teacher Retirement System of Texas purchased a new stake in shares of OPKO Health during the first quarter worth approximately $139,000. Cerity Partners LLC acquired a new stake in OPKO Health during the 1st quarter worth $36,000. CWM LLC grew its holdings in shares of OPKO Health by 961.9% during the first quarter. CWM LLC now owns 74,503 shares of the biotechnology company’s stock worth $124,000 after buying an additional 67,487 shares in the last quarter. Private Advisor Group LLC raised its position in shares of OPKO Health by 56.7% in the first quarter. Private Advisor Group LLC now owns 55,301 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 20,000 shares during the last quarter. Finally, Oak Thistle LLC acquired a new stake in shares of OPKO Health in the first quarter valued at about $26,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Analyst Upgrades and Downgrades

OPK has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, November 1st. Zacks Research upgraded OPKO Health from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $1.60 price target (down previously from $2.00) on shares of OPKO Health in a report on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research note on Wednesday, October 8th. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $2.28.

Insider Activity

In related news, CEO Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock in a transaction dated Friday, October 31st. The shares were acquired at an average cost of $1.42 per share, with a total value of $213,000.00. Following the purchase, the chief executive officer owned 214,386,448 shares of the company’s stock, valued at approximately $304,428,756.16. The trade was a 0.07% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 49.69% of the company’s stock.

OPKO Health Price Performance

NASDAQ:OPK opened at $1.28 on Friday. OPKO Health, Inc. has a 52 week low of $1.11 and a 52 week high of $2.04. The stock’s fifty day moving average is $1.45 and its two-hundred day moving average is $1.38. The company has a market capitalization of $982.66 million, a P/E ratio of -5.12 and a beta of 1.50. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.05. OPKO Health had a negative return on equity of 13.62% and a negative net margin of 28.10%.The firm had revenue of $151.67 million during the quarter, compared to the consensus estimate of $165.74 million. During the same period last year, the company earned $0.03 EPS. The company’s quarterly revenue was down 12.6% on a year-over-year basis. Equities analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.